European commission approves first crispr/cas9 gene-edited therapy, casgevy™ (exagamglogene autotemcel), for the treatment of sickle cell disease and transfusion-dependent beta thalassemia

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) announced today that the european commission has granted conditional marketing authorization to casgevy™ (exagamglogene autotemcel [exa-cel]), a crispr/cas9 gene-edited therapy. casgevy is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (scd) characterized by recurrent vaso-occlusive crises (vocs) or transfusion-dependent beta thalassemia (tdt), for whom hematopoi.
VRTX Ratings Summary
VRTX Quant Ranking